A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer

被引：7

作者：

Akaza, Hideyuki ^{[1
]}

Uemura, Hirotsugu ^{[2
]}

Tsukamoto, Taiji ^{[3
]}

Ozono, Seiichiro ^{[4
]}

Ogawa, Osamu ^{[5
]}

Sakai, Hideki ^{[6
]}

Oya, Mototsugu ^{[7
]}

Namiki, Mikio ^{[8
]}

Fukasawa, Satoshi ^{[9
]}

Yamaguchi, Akito ^{[10
]}

Uemura, Hiroji ^{[11
]}

Ohashi, Yasuo ^{[12
]}

Maeda, Hideki ^{[13
]}

Saito, Atsushi ^{[13
]}

Takeda, Kentaro ^{[13
]}

Naito, Seiji ^{[10
]}

机构：

[1] Univ Tokyo, Strateg Invest Comprehens Canc Network, Meguro Ku, 4-6-1 Komaba, Tokyo 1538904, Japan

[2] Kinki Univ, Dept Urol, Fac Med, 377-2 Ono Higashi, Osakasayama 5898511, Japan

[3] Sapporo Med Univ, Dept Urol, Sch Med, S1 W17 Chuo Ku, Sapporo, Hokkaido 0608556, Japan

[4] Hamamatsu Univ Sch Med, Dept Urol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan

[5] Kyoto Univ, Dept Urol, Grad Sch Med, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan

[6] Nagasaki Univ, Dept Urol, Grad Sch Biomed Sci, 1-7-1 Sakamoto, Nagasaki 8528501, Japan

[7] Keio Univ, Dept Urol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan

[8] Kanazawa Univ, Dept Integrat Canc Therapy & Urol, Grad Sch Med Sci, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan

[9] Chiba Canc Ctr, Dept Urol, Chuo Ku, 666-2 Nitona Cho, Chiba 2608717, Japan

[10] Harasanshin Hosp, Div Urol, Hakata Ku, 1-8 Taihakumachi, Fukuoka 8120033, Japan

[11] Yokohama City Univ, Dept Urol & Renal Transplantat, Med Ctr, Minami Ku, 4-57 Urafune, Yokohama, Kanagawa 2320024, Japan

[12] Chuo Univ, Dept Integrated Sci & Engn Sustainable Soc, Bunkyo Ku, 1-13-27 Kasuga, Tokyo 1128551, Japan

[13] Astellas Pharma Inc, Chuo Ku, 2-5-1 Nihonbashi Honcho, Tokyo 1038411, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 21卷 / 04期

关键词：

Androgen receptor inhibitor; Enzalutamide; Metastatic castration-resistant prostate cancer; ABIRATERONE ACETATE; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; CLINICAL ACTIVITY; DOCETAXEL; THERAPY; TRIAL; PREDNISOLONE; MITOXANTRONE; ANTIANDROGEN;

D O I：

10.1007/s10147-016-0952-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Trial registration: ClinicalTrials.gov NCT01284920.

引用

页码：773 / 782

页数：10

共 50 条

[1] A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
Hideyuki Akaza
Hirotsugu Uemura
Taiji Tsukamoto
Seiichiro Ozono
Osamu Ogawa
Hideki Sakai
Mototsugu Oya
Mikio Namiki
Satoshi Fukasawa
Akito Yamaguchi
Hiroji Uemura
Yasuo Ohashi
Hideki Maeda
Atsushi Saito
Kentaro Takeda
Seiji Naito
International Journal of Clinical Oncology, 2016, 21 : 773 - 782
[2] Enzalutamide for Patients with castration-resistant Prostate Cancer
Kessing, Richard
AKTUELLE UROLOGIE, 2020, 51 (01)
[3] Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study
Gacci, Mauro
Marchioni, Michele
De Francesco, Piergustavo
Natoli, Clara
Calabro, Fabio
Losanno, Tania
Gianmartin, Cito
Serni, Sergio
Doni, Laura
De Nunzio, Cosimo
De Tursi, Michele
Valeriani, Maurizio
Giacinti, Silvana
Alvarez-Maestro, Mario
Scarcia, Marcello
Ludovico, Giuseppe M.
Del Bene, Gabriella
Simone, Giuseppe
Ferriero, Mariaconsiglia
Tuderti, Gabriele
Bove, Pierluigi
Laudisi, Anastasia
Carrieri, Giuseppe
Cormio, Luigi
Verze, Paolo
La Rocca, Roberto
Falsaperla, Mario
Frantellizzi, Viviana
Greco, Francesco
Di Nicola, Marta
Schips, Luigi
Cindolo, Luca
MINERVA UROLOGY AND NEPHROLOGY, 2021, 73 (04): : 489 - 497
[4] A phase I/II study of enzalutamide in combination with indomethacin in men with castration-resistant prostate cancer (CRPC)
Leibrandt, Ryan
Ullah, Ayman Teeham
Verma, Rashmi
Gao, Allen
Lara, Primo N., Jr.
Pan, Chong-xian
Parikh, Mamta
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance
McKay, Rana R.
Kwak, Lucia
Crowdis, Jett P.
Sperger, Jamie M.
Zhao, Shuang G.
Xie, Wanling
Werner, Lillian
Lis, Rosina T.
Zhang, Zhenwei
Wei, Xiao X.
Lang, Joshua M.
Van Allen, Eliezer M.
Bhatt, Rupal S.
Yu, Evan Y.
Nelson, Peter S.
Bubley, Glenn J.
Montgomery, R. Bruce
Taplin, Mary-Ellen
CLINICAL CANCER RESEARCH, 2021, 27 (13) : 3610 - 3619
[6] Phase I results of exicorilant plus enzalutamide in patients with castration-resistant prostate cancer
Linch, M.
Liu, G.
Crabb, S. J.
Beer, T. M.
Heath, E.
Gordon, M.
de Bono, J. S.
Pashova, H. I.
Tudor, I. C.
Custodio, J. M.
Mann, G.
Morris, M. J.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1183 - S1183
[7] Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
Michaelson, M. D.
Bellmunt, J.
Hudes, G. R.
Goel, S.
Lee, R. J.
Kantoff, P. W.
Stein, C. A.
Lardelli, P.
Pardos, I.
Kahatt, C.
Nieto, A.
Cullell-Young, M.
Lewis, N. L.
Smith, M. R.
ANNALS OF ONCOLOGY, 2012, 23 (05) : 1234 - 1240
[8] A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
Schweizer, Michael T.
Haugk, Kathleen
McKiernan, Jozefa S.
Gulati, Roman
Cheng, Heather H.
Maes, Jessica L.
Dumpit, Ruth F.
Nelson, Peter S.
Montgomery, Bruce
McCune, Jeannine S.
Plymate, Stephen R.
Yu, Evan Y.
PLOS ONE, 2018, 13 (06):
[9] Phase I Study of Entinostat in Combination with Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
Lin, Jianqing
Elkon, Jacob
Ricart, Brittany
Palmer, Erica
Zevallos-Delgado, Christian
Noonepalle, Satish
Burgess, Brooke
Siegel, Robert
Ma, Yan
Villagra, Alejandro
ONCOLOGIST, 2021, 26 (12): : E2136 - E2142
[10] Phase I study of entinostat in combination with enzalutamide for treatment of patients with castration-resistant prostate cancer.
Lin, Jianqing
Elkon, Jacob Matt
Ricart, Brittany
Burgess, Brooke
Palmer, Erica
Siegel, Robert S.
Ma, Yan
Villagra, Alejandro
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)

← 1 2 3 4 5 →